Results 51 to 60 of about 48,914 (162)

Pediatric Cardio-Oncology: Screening, Risk Stratification, and Prevention of Cardiotoxicity Associated with Anthracyclines

Children
Anthracyclines have significantly improved the survival of children with malignant tumors, but the associated cardiotoxicity, an effect now under the purview of pediatric cardio-oncology, due to its cumulative and irreversible effects on the heart ...
Xiaomeng Liu, Shuping Ge, Aijun Zhang
doaj   +1 more source

CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced Cardiomyopathy

JACC. CardioOncology, 2020
Anthony J. Kanelidis, MD, Jayant Raikhelkar, MD, Gene Kim, MD, Gabriel Sayer, MD, Michael R. Bishop, MD, Tamar S. Polonsky, MD, MSCI, Nir Uriel, MD, MSc   +6 more
doaj   +1 more source

Post-marketing safety evaluation of anthracycline for acute myeloid leukemia treatment: a real-world pharmacovigilance analysis. [PDF]

Front Pharmacol
Wang Y, Liu Q, Xu J, Yang F, Wang M, Lu H, Wu J, Zhang A, Zhang X, Wu D, Qiu H.   +10 more
europepmc   +1 more source

Anthracycline-induced cardiorenal toxicity: from molecular mechanisms to clinical management. [PDF]

Front Cardiovasc Med
Jiao L, Yuan C, Wang L, Zhao Y, Zhang G, Yang X, Gao Y, Yang F, Li X, An N, Shang H, Xing Y.   +11 more
europepmc   +1 more source

Anthracyclines and the heart [PDF]

Heart, 1994
openaire   +2 more sources

New-Onset Atrial Fibrillation as an Early Marker of Anthracycline-Associated Cardiotoxicity and Mortality: A Retrospective Study. [PDF]

Cureus
Homeniuk A, Karthikeyan G, Atrash A.
europepmc   +1 more source

Variability in anthracycline dose conversions and cardiotoxicity monitoring: insights from hospital pharmacists on institutional protocols in oncology practice. [PDF]

Support Care Cancer
Ditta SA, Jongbloed F, Manintveld OC, Brugma JD, Wlazlo N, Bos MEMM, van der Kuy HM, Mathijssen RHJ.   +7 more
europepmc   +1 more source

Efficacy evaluation of Wenxin Keli in treating anthracycline-induced atrial arrhythmias (WARMA study): protocol for a multicenter, randomized, double-blind, placebo-controlled clinical trial. [PDF]

Front Cardiovasc Med
Jiao L, An N, Li X, Liu X, Miao L, Hu G, Jiang Y, Yang X, Gao Y, Shang H, Xing Y.   +10 more
europepmc   +1 more source

Dynamic, anthracycline-induced chromatin alterations enable ALDH1 expression as a mechanism of inducible leukemia resistance development. [PDF]

Blood Res
Vlahopoulos SA.
europepmc   +1 more source

Development and validation of a nomogram for predicting grade 4 neutropenia in patients with breast cancer undergoing anthracycline-based chemotherapy. [PDF]

Am J Transl Res
Shi J, Zhao F, Qiu T, Huang S, Li Y, Ma J, Zhao J.   +6 more
europepmc   +1 more source